Jingyu Yu

Also affiliated with Shanghai Public Health Clinical Center, Chinese Institute for Brain Research, Huashan Hospital, Shanghai Center for Brain Science and Brain-Inspired Technology

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer”.

FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0991

N/A

2.9DataRank · unranked

108 citations

Mirat Shah, Gwynn Ison, Haley Gittleman, Mallorie H. Fiero, Ankit Shah +20 more

FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-3652

N/A

0.773DataRank · unranked

172 citations

Tatiana M. Prowell, Jennifer Gao, Laura L. Fernandes, Emily Li, Xiling Jiang +29 more

FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-3247

N/A

0.553DataRank · unranked

39 citations

Christy Osgood, Anup Amatya, Mallorie H. Fiero, C.J. George Chang, Tiffany K. Ricks +32 more

FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2334

N/A

0DataRank · unranked

45 citations

Chana Weinstock, Lijun Zhang, Mallorie H. Fiero, Miao Zhao, Eias Zahalka +14 more

FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4557

N/A

0DataRank · unranked

164 citations

Christy Osgood, Harpreet Singh, Haw-Jyh Chiu, Tiffany K. Ricks, Edwin C.Y. Chow +14 more

FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1393

N/A

0DataRank · unranked

32 citations

William F. Maguire, Chana Weinstock, Hui Zhang, Xin Gao, Fang Li +14 more

FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-1388

N/A

0DataRank · unranked

13 citations

Mirat Shah, Lijun Zhang, Joyce Cheng, Mary Kate Bonner, Melissa A. Pegues +22 more